Latest Conference Articles

Victoria Garcia-Albea, NP, discussed the learning curve dermatology NP fellows experience and the need for greater dermatology education for APPs.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.

Leon Kircik, MD, discusses the allosteric binding mechanism and safety profile data of zasocitinib in hard-to-treat psoriasis presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Leon Kircik, MD, outlines phase 3 zasocitinib data on palmoplantar psoriasis skin clearance presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Leon Kircik, MD, discusses zasocitinib scalp psoriasis clearance rates from the LATITUDE 1 and 2 trials presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Explore the top dermatology conferences and meetings happening this month and let us know which ones you'll be attending!

Catch up on the biggest clinical updates, expert insights, and exclusive interviews from Elevate-Derm Summer 2026 in San Diego, California.

Catch Up on Coverage From Day 5 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 4 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 3 of the 3rd Annual Elevate-Derm Summer Conference

Faculty at Elevate-Derm Summer 2026 discussed the expanding role of oral JAK inhibitors in pediatric dermatology, emphasizing earlier intervention, individualized patient selection, safety monitoring, and family-centered counseling.

Advances in vitiligo, hidradenitis suppurativa, and hair loss were among the key trends Chantel Hillstead, APRN, said APPs should watch.

Lisa Swanson, MD, discussed strategies for counseling patients on JAK inhibitor safety and where she sees the drug class expanding next in a recent Dermatology Times interview.

At Elevate-Derm, Justin Love, PA-C, explains why planning is essential for successful and meaningful patient discussions.

Oyetewa Asempa, MD, discussed the importance of scalp examination, trichoscopy, and culturally informed communication when evaluating patients with hair loss during a recent Dermatology Times interview

Victoria Garcia Albea, NP, discussed safety monitoring, patient selection, and laboratory screening considerations for oral JAK inhibitors at Elevate-Derm summer 2026

Catch Up on Coverage From Day 2 of the 3rd Annual Elevate-Derm Summer Conference

Elevate-Derm expert panel offers practical JAK inhibitor pearls on cholesterol, comorbid autoimmune disease, and shared decision-making.

At Elevate Derm, Lisa Swanson, MD, discussed earlier oral JAK inhibitor use for alopecia areata and selecting appropriate patients.

RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.

At Elevate-Derm, Justin Love, PA-C, urged clinicians to pair diagnostic expertise with emotional intelligence and thoughtful investigation.

San Diego meeting highlights inflammatory dermatoses, skin cancer, alopecia, and emerging therapeutic advances

Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference

Linda Stein Gold, MD, presents tapinarof cream as a long-term, nonsteroidal option for pediatric atopic dermatitis based on data presented at the 2026 Society for Pediatric Dermatology Annual Meeting.

Catch up on all of our coverage from this year's Society for Pediatric Dermatology annual meeting.

Learn from Adnan Mir, MD, PhD, on how better biopsies and direct lab communication help APPs and dermatopathologists boost pediatric skin diagnoses and outcomes.

Lawrence Eichenfield, MD, presented phase 3 results showing lebrikizumab boosts skin clearance, eases itch, and looks safe for infants through teens with moderate to severe atopic dermatitis.